Hematologic Oncology Update
Dr. Neil Love
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
Episodes
Mentioned books
Apr 1, 2026 • 25min
Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.
Mar 23, 2026 • 24min
CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.CME information and select publications here.
Mar 21, 2026 • 29min
Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.
Mar 13, 2026 • 1h 3min
CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah
Dr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.CME information and select publications here.
Mar 11, 2026 • 47min
Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting
Prof Constantine Tam from Monash University in Melbourne, Australia, reviews recent datasets and discusses their implications for current and future management of chronic lymphocytic leukemia.CME information and select publications here.
Mar 9, 2026 • 19min
Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.
Mar 4, 2026 • 24min
Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.
Feb 18, 2026 • 58min
Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators
Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations.CME information and select publications here.
Feb 13, 2026 • 17min
Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review
Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.
Feb 6, 2026 • 1h 30min
Immune Thrombocytopenia — ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.CME information and select publications here.
